checked
things people say about psychiatric medication, diagnosis and the health system, on podcasts and on youtube, taken to the primary record. not a gotcha. the people repeating these claims are mostly right to distrust the standard story, and the only honest way to join that conversation is to go and look, and to say so just as loudly when the claim holds up.
how it works: we quote one sentence, with the show, the date and the timestamp, and link the original. we pull the claim apart into assertions and check each one against the record itself (pubmed abstracts, fda labels, cms and medicaid files, samhsa, nimh, gao, court dockets), never from memory and never from advocacy sites. each assertion gets one of six verdicts, and the page says what the data cannot answer, our own method included. speakers are described by their role on the show, not named.
the six verdicts
- confirmedthe primary source says it, at that magnitude
- undersoldthe real number is bigger, or worse, than claimed
- overstateddirectionally right; magnitude or certainty inflated
- misattributeda real number attached to the wrong thing
- unverifiableno method, no file, or the data cannot answer it
- falsethe primary source contradicts it
the ratio, so far: 485 of 830 assertions came back confirmed or undersold. if that number stays low for long, the pipeline is selecting for outrage and gets re-pointed.
every check
- confirmedPsychiatry & Psychotherapy Podcast2026-11-212 primary sources
did a 2026 pharmacovigilance study find a 2.35 reporting odds ratio for wernicke's with glp-1 drugs?
“they saw a relative odds ratio of 2.35” — a guest, a medical student, at 02:42
the number is real and correctly attached. a pharmacovigilance study published in january 2026 found a reporting odds ratio of 2.35 (95% ci 1.38-4.01) for wernicke's encephalopathy with glp-1 receptor agonists compared with other medications in the fda adverse event reporting system.
- confirmedPsychiatry & Psychotherapy Podcast2026-11-212 primary sources
did a 1982 norwegian autopsy study find wernicke's lesions in 0.8% of 8,735 autopsies?
“they showed in a point eight percent of autopsy patients had lesions of orna keys and cephalopathy” — a host, a psychiatrist, at 30:57
The claim matches the record. A 1982 study from Ullevål Hospital in Oslo reviewed 8,735 autopsies and found 70 cases of Wernicke's encephalopathy, which is 0.8%.
- undersoldPsychiatry & Psychotherapy Podcast2026-11-214 primary sources
do about 1% of autopsies show wernicke's encephalopathy, mostly missed in life?
“around one percent of autopsy series have orna keys and cephalopathy found you know and most of the cases are not diagnosed in life” — a host, a psychiatrist, at 31:34
Both parts of the claim hold up. Unselected autopsy series do find wernicke's encephalopathy lesions in roughly 1% to 2% of brains, and in every series we read most of those cases had not been diagnosed before death.
- unverifiablePsychiatry & Psychotherapy Podcast2026-11-212 primary sources
did a review of 12 studies and 5,510 patients find the wernicke triad in only a third?
“It looked at 12 retrospective studies from multiple countries and it included 5,510 patients” — a guest, a medical student, at 50:09
the review is real and the numbers hold: a 2025 systematic review and meta-analysis in neuroepidemiology pooled 12 studies with 5,510 patients with wernicke's encephalopathy and found the classic triad in 32.7% of them, which is about one third.
- overstatedHuberman Lab2026-11-195 primary sources
does bupropion take quit rates from about 5% to about 20% for smoking and vaping?
“it moves that number of 5% success rate to about what one sees with the clinical hypnosis to about 20% of people will successfully overcome their nicotine or I should say their smoking or vaping addiction.” — a host, at 29:43
the 20% figure holds up. in the fda-reviewed trials of bupropion for quitting cigarettes, roughly one in five people on the drug were still continuously abstinent at six months to a year (19% at 26 weeks in one trial, 23% at 52 weeks in another).
- overstatedHuberman Lab2026-11-192 primary sources
do 75% of quitters relapse within a week, and do 95% of quit attempts fail?
“75% of people relapse within one week, and overall failure rates are 95%” — a host, at 33:25
the core of it holds for cigarettes: a systematic review of people who quit smoking without treatment found that most relapse happens in the first 8 days, and only about 3-5% of those unaided attempts last 6-12 months. that is a 95-97% failure rate per unaided attempt.
- overstatedHuberman Lab2026-11-195 primary sources
did 23% of smokers quit after one session of stanford's hypnosis protocol?
“The success rate with this particular hypnosis developed at Stanford School of Medicine by Dr. David Spiegel is 23% of people who do this hypnosis one time succeed in quitting smoking.” — a host, at 27:47
the number is real. a 1993 american journal of psychiatry paper from the stanford lab that developed the protocol reports that 23% of 226 smokers given one session with self-hypnosis stayed abstinent for 2 years.
- misattributedHuberman Lab2026-11-194 primary sources
do 65% of smokers who quit unaided relapse within a year
“of the 5% that succeed in quitting, a full 65% of them relapse within a year.” — a host, at 25:00
the "5%" is right: a systematic review of smokers who quit without treatment puts long-term success at about 3-5% (still off cigarettes 6-12 months later). relapse is also the normal outcome for unaided quitters, and nothing in the record says otherwise.
- falsePsychopharmacology and Psychiatry Updates2026-11-186 primary sources
does lumateperone cost $18 a month like generic aripiprazole and quetiapine?
“generic aeropipousol costs $16 a month. The utipine immediate release costs $9 a month, whereas brex pipousol, about $1500 a month and Lumetepiron $18 a month.” — a guest, research editor at the Psychopharmacology Institute and medical director of depressioneducation.org, at 06:44
Three of the four numbers fit the federal record. Brexpiprazole really does run about $1,500 a month: pharmacies pay about $49.50 a tablet, roughly $1,485 for 30. Generic aripiprazole and immediate-release quetiapine really do cost a few dollars a month at the pharmacy's purchase price, so retail cash prices of $16 and $9 are believable.
- confirmedPsychopharmacology and Psychiatry Updates2026-11-182 primary sources
does the label give aripiprazole a 2-5 mg start and a 15 mg/day maximum as an add-on for depression
“The labeled adjunctive dose starts at 2-5 mg a day. The maximum is 15 mg a day.” — a host, at 08:18
the speaker has it right. the current u.s. label for aripiprazole in adjunctive major depressive disorder gives a starting dose of 2 to 5 mg/day and a maximum of 15 mg/day, word for word.
- confirmedPsychopharmacology and Psychiatry Updates2026-11-184 primary sources
does lumateperone cost about $1,800 a month in the us
“Luma teperone runs about $1,800 a month.” — a host, at 09:27
the host's figure holds. Lumateperone is a once-daily capsule, and in the US a month of it costs roughly $1,700 before insurance in every federal record we checked, so "about $1,800" is close. A figure of $18 a month is about a hundredth of the drug's price.
- overstatedPsychopharmacology and Psychiatry Updates2026-11-183 primary sources
did about 1 in 12 us adults have a major depressive episode in the past year?
“Roughly one in 12 US adults had a major depressive episode in the past year.” — a host, at 01:26
"roughly one in 12" fit every federal estimate from 2021 through 2024: 8.5, 8.8, 8.5 and 8.2 percent of us adults had a past-year major depressive episode. the 2024 figure, 8.2 percent or 21.4 million adults, is essentially one in 12.
- confirmedHuberman Lab2026-11-162 primary sources
does clinicaltrials.gov list about 306 clinical trials on psilocybin?
“There's 306 clinical trials on psilocybin at clinicaltrials.gov as of this morning.” — a guest, a mycologist, at 1:32:45
the number holds up. when we queried the ClinicalTrials.gov registry the day after the episode aired, it returned 310 studies listing psilocybin as an intervention, 300 of them interventional trials. "about 306" matches what the registry shows.
- falseHuberman Lab2026-11-165 primary sources
has the fda approved 25 mg of psilocybin, or 2.5 g of mushrooms, as a standard dose?
“The FDA has approved 25 millig or 2.5 g of mushrooms as the standard dose. That's why most all clinical trials are 25 milligrams.” — a guest, a mycologist, at 1:39:28
25 mg of synthetic psilocybin is the dose used in the late-stage industry trials, including both phase 3 trials behind the first psilocybin application now before the FDA. At an average potency of about 1%, 2.5 g of dried mushrooms works out to roughly 25 mg on paper.
- confirmedHuberman Lab2026-11-162 primary sources
did about 2.5% of americans report using psilocybin in the past year
“2.5% of Americans admitted they use psilocybin last [clears throat] year.” — a guest, a mycologist, at 1:14:55
the figure holds. the first federal survey to ask about psilocybin by name, the 2024 national survey on drug use and health, puts past-year use at 2.8% of people aged 12 and older, about 8.0 million people. the confidence interval runs from 2.5% to 3.1%, so "about 2.5%" is the right size, if anything a little low.
- overstatedHuberman Lab2026-11-163 primary sources
were 90% of smokers given psilocybin off cigarettes a year later, versus the nicotine patch?
“90% of people addicted to tobacco compared to the nicotine patch one year later not smoking cigarettes.” — a guest, a mycologist, at 1:15:57
the direction is right. in the one randomized trial that compared psilocybin with the nicotine patch, about four times as many people in the psilocybin arm stayed off cigarettes. it was 40.5% versus 10.0% on prolonged abstinence at six months.
- misattributedThe Carlat Psychiatry Podcast2026-11-163 primary sources
does fda antidepressant labeling recommend screening for bipolar disorder with a questionnaire?
“They recommend screening for bipolar disorder with a tool like the mood disorder questionnaire before starting any antidepressant.” — a host, a psychiatrist, at 20:09
this part is right: FDA labeling for antidepressants does tell prescribers to screen for bipolar disorder before starting treatment. Current labels word it as screening for a personal or family history of bipolar disorder, mania or hypomania before starting "this drug or another antidepressant", and older-format labels carry the same instruction.
- undersoldThe Peter Attia Drive2026-11-165 primary sources
does methylene blue block mao and risk serotonin toxicity with ssris? yes, even at standard doses
“as you know, it can inhibit monomine oxidasis which detoxify dopamine and serotonin and people on serotonin” — a guest, a mitochondrial biologist (not a physician), at 2:01:43
the core of this is right. methylene blue inhibits monoamine oxidase, specifically MAO-A, and when it is combined with SSRIs and other serotonergic drugs it can cause serotonin toxicity, sometimes fatal. that is now a boxed warning on the FDA label.
- misattributedThe Carlat Psychiatry Podcast2026-11-163 primary sources
do 1 in 25 women with untreated postpartum psychosis kill their children?
“Without it, one in 25 go on to murder their children.” — a host, a psychiatrist, at 07:01
postpartum psychosis is a psychiatric emergency, and the risk of a mother harming or killing her baby is real. the 4% figure (about 1 in 25) is real too. it appears in the literature and has been repeated in american clinical reviews for years.
- overstatedThe Carlat Psychiatry Podcast2026-11-162 primary sources
did 98% of women with postpartum psychosis reach full recovery in one study?
“With that approach, 98 percent of women reached full recovery in one study.” — a host, a psychiatrist, at 06:52
the number is real. in the 2015 american journal of psychiatry cohort of 64 women admitted for first-onset postpartum psychosis or mania, 98.4% reached complete remission under a stepped protocol of benzodiazepines, then antipsychotics, then lithium, and none needed ect.
- overstatedThe Carlat Psychiatry Podcast2026-11-162 primary sources
do half of women with postpartum psychosis go on to develop bipolar disorder?
“Half of women with postpartum psychosis go on to develop full bipolar disorder.” — a host, a psychiatrist, at 04:43
a large share of women whose first psychosis comes after childbirth do go on to have mood or psychotic episodes outside the postpartum period, and when they do, the diagnosis is mostly bipolar disorder. in the long-follow-up studies, the share of women whose illness stayed tied to childbirth sits a little under half, so "half" is a fair round figure for that group.
- undersoldPsychopharmacology and Psychiatry Updates2026-11-132 primary sources
is bupropion cut by about half in child-pugh b or c liver disease? the label cuts it more
“But buproprian, in child puke BC, you should reduce the dose by about half.” — a guest, Dr. Kevin A. Severino, lecturer on addiction psychopharmacology, at 07:17
the speaker has the direction and the patient group right. the bupropion labels group child-pugh class b and c together (scores 7 to 15) and require a lower dose for that group.
- confirmedPsychopharmacology and Psychiatry Updates2026-11-133 primary sources
is extended-release injectable buprenorphine not recommended in moderate or severe liver impairment?
“extended release injections. It's not recommended with moderate or severe hepatic impairment, again, because the formulation doesn't allow for rapid dose adjustment.” — a guest, Dr. Kevin A. Severino, lecturer on addiction psychopharmacology, at 03:58
The claim holds. Both extended-release buprenorphine injections sold in the US have current FDA labeling that says "moderate to severe hepatic impairment: not recommended". Both labels give the reason the speaker gave: the long-acting depot means a dose change does not quickly change buprenorphine levels in the blood.
- misattributedPsychopharmacology and Psychiatry Updates2026-11-133 primary sources
does the combination film label say to start severe liver impairment on buprenorphine alone?
“The FDA label for the combination film recommends starting severe hepatic impairment on buprenorphine alone.” — a host, at 01:47
the combination-film label does steer away from buprenorphine/naloxone in severe hepatic impairment: it says the products are "not recommended" (section 5.12) and "should be avoided" (section 8.6) in that group. the label also contains a sentence about starting treatment on buprenorphine without naloxone, so the speaker is mixing two real parts of the label.
- confirmedThe Diary of a CEO2026-11-124 primary sources
did the cochrane review find amyloid-targeting alzheimer's drugs don't meaningfully slow decline?
“They found that the drugs basically have no meaningful effect in slowing the progression, much less leading to improvement.” — a guest, a neurologist, at 36:20
the speaker has the review right. the 2026 cochrane review of amyloid-targeting antibodies called their effect on cognition and dementia severity at 18 months "trivial", and said removing amyloid "does not appear" to bring clinically meaningful improvement. people on the drugs kept declining in every trial, so "much less leading to improvement" holds as well.
- misattributedThe Diary of a CEO2026-11-125 primary sources
did the cochrane review pool 17 anti-amyloid trials of 18 months each with 20,342 people?
“this cockrine analysis looked at 20,342 individuals in 17 different studies 18 months each study” — a guest, a neurologist, at 35:58
the review is real, it is a cochrane review of amyloid-beta-targeting antibodies, and two of its headline numbers match exactly: 17 studies and 20,342 participants. it was published on 16 april 2026, so "just published" is a fair description seven months later.
- misattributedPsychopharmacology and Psychiatry Updates2026-11-132 primary sources
did 38% of programs treat a past liver transplant as a reason not to start methadone?
“There's a 2017 survey, which is Fleming et al 2017, 38% of programs considered a relative contraindication if somebody had had liver transplant for starting them on methadone.” — a guest, Dr. Kevin A. Severino, lecturer on addiction psychopharmacology, at 06:17
the survey is real, it was published in 2017, and its lead author is the one the speaker named. the 38% is also real: 37.7% of responding programs called opioid substitution therapy a relative contraindication.
- misattributedThe Diary of a CEO2026-11-124 primary sources
is the uk's £33 million going to a trial of metformin and atomoxetine in alzheimer's?
“the government has uh put up 33 million pounds 44 million to begin a study of two medicines in the treatment of Alzheimer's disease.” — a guest, a neurologist, at 08:30
the trial is real and the drugs are right. AD-SMART is a UK phase 3 platform trial that tests metformin and atomoxetine against a placebo in people with Alzheimer's disease. Its main results are measured at 18 months, and it is government-backed in part.
- overstatedThe Diary of a CEO2026-11-123 primary sources
do about 7.6 million people in the us have alzheimer's disease?
“the 7.6 million Alzheimer's patients.” — a guest, a neurologist, at 03:22
the speaker has the size of the problem right. the most recent national estimate is 7.4 million americans age 65 and older living with clinical alzheimer's dementia in 2026, and 7.6 million is about 3% above that.
- misattributedHuberman Lab2026-11-093 primary sources
did the speaker's paper show hallucinogen er visits rise as use rises?
“We published a paper looking at the number of uh ED visits and hospitalizations as a result of hallucinogens. And what we have shown is that as use goes up, the number of ED related harms” — a guest, director of a dual diagnosis addiction clinic at Stanford (psychiatrist), at 1:05:49
the paper is real and says what the speaker says it says about visits: a stanford psychiatry group published it in addiction in 2024, and it found hallucinogen-associated emergency department visits in california rose 54% from 2016 to 2022 (2,260 to 3,476), with hospitalizations up about 55%. hallucinogen use did rise nationally over the same years, according to federal survey data.
- misattributedHuberman Lab2026-11-094 primary sources
is ketamine fda approved for treatment-resistant depression? esketamine is, ketamine is not
“So ketamine is FDA approved for the treatment of treatment refractory depression.” — a guest, director of a dual diagnosis addiction clinic at Stanford (psychiatrist), at 2:04:49
the fda has approved a drug made from ketamine for treatment-resistant depression. it is esketamine nasal spray, approved march 5, 2019, and the current label also allows it to be used on its own.
- confirmedHuberman Lab2026-11-095 primary sources
do people who quit alcohol and smoking together do better than those who keep smoking?
“there are studies showing that for people who are addicted to alcohol and nicotine products who give up both at the same time compared to people who just give up alcohol but keep smoking” — a guest, director of a dual diagnosis addiction clinic at Stanford (psychiatrist), at 19:34
the studies exist. prospective cohorts of people with alcohol problems keep finding that those who stop smoking too do better on drinking than those who keep smoking. in one, alcohol-dependent men went through a combined alcohol-and-smoking program, and the ones who quit cigarettes were about twice as likely to stay abstinent from alcohol for a year.
- unverifiableHuberman Lab2026-11-092 primary sources
are half of referrals to a stanford adolescent addiction clinic for digital media addiction?
“Our adolescent clinic now about 50% of the referrals are for digital media addiction in some form.” — a guest, director of a dual diagnosis addiction clinic at Stanford (psychiatrist), at 03:45
the speaker runs the clinic and is describing its own intake, which they would know firsthand, and the clinic does treat behavioral addictions including video games. the wider record also shows that addiction-like use of screens among adolescents is common and tracks with worse mental-health outcomes, so a heavy load of these referrals at a specialty addiction clinic is plausible.
- confirmedThe Carlat Psychiatry Podcast2026-11-092 primary sources
did clinicians miss about 30% of psychotic depression cases in one study?
“In one study, clinicians missed 30% of cases of psychotic depression. This wasn't postpartum, just psychotic depression.” — a host, a psychiatrist, at 11:03
the study exists and the number holds up: in a 2008 analysis at four academic medical centers, psychotic depression had not been diagnosed before research assessment in 27% of chart diagnoses, which is close to the "30%" quoted on air.
- confirmedThe Carlat Psychiatry Podcast2026-11-092 primary sources
did a study find nearly half of women with postpartum psychosis said symptoms waxed and waned?
“In a new study of postpartum psychosis, nearly half the women said that their symptoms waxed and waned.” — a host, a psychiatrist, at 10:01
the study is real and the number holds. a large postpartum psychosis cohort from the massachusetts general hospital postpartum psychosis project, published in molecular psychiatry, found that 45.7% reported their symptoms waxed and waned and 51.9% reported more steady symptoms. "nearly half" is a fair way to say 45.7%.
- unverifiableThe Carlat Psychiatry Podcast2026-11-092 primary sources
did residents catch psychotic depression more often than attendings in the missed-diagnosis study?
“The residents in that study detected psychosis better than their attendings did.” — a host, a psychiatrist, at 11:18
the study is real, and it was designed to ask this question. a 2008 paper on missed psychotic depression at 4 academic medical centers listed the physician's level of training as one of the three factors it set out to test, and it found psychotic depression went undiagnosed in 27% of 130 diagnoses.
- overstatedThe Carlat Psychiatry Podcast2026-11-092 primary sources
did a review find six wernicke encephalopathy cases on semaglutide, mostly women in their 40s?
“The authors found six case reports of warnakies on semi-glutide. Most were women in their 40s who had taken semi-glutide for about five months before symptoms began.” — a host, a psychiatrist, at 13:38
the review is real and the speaker's numbers match it: a systematic review in the journal Obesity found six cases of wernicke encephalopathy after semaglutide prescribed for weight loss, four of the six were women, the mean age was 47.2, and the mean time on semaglutide was 4.9 months.
- confirmedPsychopharmacology and Psychiatry Updates2026-11-083 primary sources
did a european psychiatry review find antipsychotics helped catatonia in 60% of trials and harmed in 10%?
“The main finding of the review is that antipsychotics were useful for catatonia in 60% of trials, but harmful in 10%.” — a guest, Dr. Scott Beach (psychiatrist presenting the review), at 06:05
the numbers are right. a 2025 systematic review in european psychiatry found antipsychotic use was judged beneficial in 60.0% of 175 treatment episodes and harmful in 10.9%, and the speaker's "10%" is that figure rounded down slightly.
- undersoldPsychopharmacology and Psychiatry Updates2026-11-083 primary sources
did the european psychiatry catatonia review include 79 articles, 175 trials and 100 patients?
“The authors ultimately included 79 articles involving 175 antipsychotic trials in 100 patients.” — a guest, Dr. Scott Beach (psychiatrist presenting the review), at 05:11
the review exists and the speaker named it correctly: a 2025 systematic review in European Psychiatry on antipsychotics in catatonia included 79 articles and 175 antipsychotic trials. the speaker had both of those numbers right.
- misattributedPsychopharmacology and Psychiatry Updates2026-11-083 primary sources
did only 41% of patients in the catatonia review get a benzodiazepine before the antipsychotic?
“Only 41% of patients in these reports had been given a benzodiazepine prior to the antipsychotic.” — a guest, Dr. Scott Beach (psychiatrist presenting the review), at 05:28
The 41% figure is real, and it comes from the review the speaker named: a 2025 systematic review in European Psychiatry on using antipsychotics in catatonia. The review's own abstract says "only 41.1% of the patients" had a prior benzodiazepine trial, so the speaker repeated the paper's headline wording almost word for word.
- misattributedPsychopharmacology and Psychiatry Updates2026-11-082 primary sources
did nearly two-thirds of patients in the catatonia review have psychotic disorders?
“the authors report that nearly two-thirds of patients in the review had psychotic disorders.” — a guest, Dr. Scott Beach (psychiatrist presenting the review), at 06:05
the number is real and the speaker reported it correctly. the european psychiatry systematic review of antipsychotics in catatonia says psychotic disorders were the most common underlying cause, at 62.9% in its results section and 65.8% in its abstract. "nearly two-thirds" is a fair reading of either figure.
- overstatedHuberman Lab2026-11-054 primary sources
are mental disorders becoming more common in modern times?
“we will decrease our modern lifestyle diseases, but also these increasing mental diseases that we see in these modern lifestyle times.” — a guest, Dr. Susanna Søberg, researcher on cold and heat exposure, at 31:14
more people are living with a mental disorder than ever before: the global burden of disease estimate went from 654.8 million cases in 1990 to 970.1 million in 2019, a 48.1% rise. in the united states, the share of high school students reporting persistent sadness or hopelessness also climbed for most of the last decade, from 30% in 2015 to 42% in 2021.
- overstatedHuberman Lab2026-11-053 primary sources
does inflammation raise the risk of depression, anxiety and alzheimer's disease?
“that inflammation increases the risk of depression and anxiety and Alzheimer's disease” — a guest, Dr. Susanna Søberg, researcher on cold and heat exposure, at 31:05
for depression, the claim holds up. higher inflammatory markers come before later depression in long-term studies, and genetic evidence points to the IL-6 signaling pathway as a plausible cause, not just a bystander.
- overstatedHuberman Lab2026-10-265 primary sources
can cbt or a beta blocker help people overcome a fear of public speaking?
“people can use cognitive behavioral therapy or a beta blocker for that matter to successfully overcome that” — a host, a neuroscientist, at 1:43:47
the cbt half holds up: a 2019 meta-analysis of 30 randomized trials found psychological treatments, mostly cognitive-behavioral, reduced fear of public speaking by a moderate-to-large amount, and the gains grew after treatment ended. beta blockers have some support too: in a randomized trial, one 40 mg dose of propranolol before a videotaped speech lowered the anxiety observers could see in anxious speakers.
- overstatedPsychEd: Educational Psychiatry Podcast2026-11-015 primary sources
is dialectical behavior therapy the gold standard for borderline personality disorder?
“It is the gold standard for borderline personality disorder and can also be used more generally to better cope with suicidal thoughts, self-harm, substance use, post-traumatic stress disorder,” — a host, a psychiatry resident, at 06:07
dialectical behavior therapy is one of the two most-tested psychotherapies for borderline personality disorder. In randomized trials it beats usual care on borderline symptom severity, how often people self-harm, and day-to-day functioning. A trial of a version adapted for ptsd also did well, and there is early positive data for binge eating and for people who have both borderline personality disorder and substance use problems.
- overstatedHuberman Lab2026-11-024 primary sources
has research proven that meditation physically changes the brain?
“They've proven that meditation literally alters your brain.” — a guest, an author (The Laws of Human Nature, Mastery), at 22:39
meditation does measurably change what the brain is doing: a 2016 meta-analysis of 78 functional imaging studies found consistent, medium-sized activation and deactivation patterns during practice, and long-term meditators show average structural differences from non-meditators. the part that has not been "proven" is that meditation causes lasting changes in brain structure.
- confirmedHuberman Lab2026-11-023 primary sources
are about 85% of near-death experiences positive, with the rest distressing or hellish?
“the studies of near-death experiences, about 85%, I'm just throwing out that number, are positive, but then there's the hellish near-death experience.” — a guest, an author (The Laws of Human Nature, Mastery), at 40:57
the number holds up. the speaker said they were "just throwing out" 85%, and it still lands inside the published range. a 2019 study classified 14% of 123 near-death accounts as distressing, which leaves 86% as the classic pleasant kind. a 2014 review in a medical journal puts the distressing share at up to one in five.
- overstatedThe Peter Attia Drive2026-10-264 primary sources
do bereaved people who remember the good times recover faster?
“the people who recover faster from um the loss of a loved one um are people who um remember the positive meaningful time together.” — a guest, a psychologist and neuroscientist, at 2:29:10
the direction is right. in the studies we read, bereaved people who can call up positive memories of the person who died, or who show real positive emotion while talking about them, have less grief and do better over time than people who can't.
- misattributedHuberman Lab2026-11-025 primary sources
does right-hemisphere stroke often cause sudden crying and heightened emotion?
“stroke the right side of the brain affecting the right side of the brain often has that effect on stroke victims.” — a guest, an author (The Laws of Human Nature, Mastery), at 24:40
this part is true: after a stroke, sudden crying or emotion that is hard to control (called post-stroke emotionalism) is common. it affects roughly one survivor in five in the first months, so "often" is a fair word.
- falseHuberman Lab2026-10-225 primary sources
do omega-3 supplements substantially lower the odds of depression?
“I do think there's a category of supplements that can greatly enhance the probability of offsetting depression and maybe even improve mood directly or indirectly.” — a host, at 26:32
the "may improve mood" part has some support. in people who already have depression, pooled placebo-controlled trials find omega-3 supplements lower symptom scores by a small, statistically detectable amount, and some meta-analyses find a larger effect for formulas that are mostly EPA.
- unverifiablePsychopharmacology and Psychiatry Updates2026-11-024 primary sources
did prazosin beat placebo 64% to 27% in the 2013 soldier trial, with a number needed to treat of 2.7?
“The score is showed 64% responders on Prazoson, 27% on placebo, number needed to treat 2.7,” — a guest, Dr. David Osser, psychiatrist treating PTSD in the VA system, at 06:31
The trial is real and the speaker describes it correctly: a 2013 randomized, placebo-controlled trial in 67 active-duty soldiers back from Iraq and Afghanistan, which found prazosin beat placebo on global function measured by the clinical global impression scale. The number needed to treat is also right if the rates are right: 64% minus 27% leaves a gap of 37 points, and 1 divided by 0.37 is 2.7.
- overstatedPsychopharmacology and Psychiatry Updates2026-11-024 primary sources
were seven of ten placebo-controlled prazosin trials in ptsd positive?
“Seven of the ten were positive.” — a guest, Dr. David Osser, psychiatrist treating PTSD in the VA system, at 03:56
the count of ten is about right: a 2025 meta-analysis found ten placebo-controlled prazosin trials in PTSD, and more of them favored prazosin than not. pooled across trials, prazosin still beats placebo on nightmares.
- confirmedPsychopharmacology and Psychiatry Updates2026-11-023 primary sources
are there 10 placebo-controlled trials of prazosin for sleep and other problems in ptsd?
“We now have 10 placebo-controlled trials that are in the literature of Prazoson for sleep and other problems in PTSD.” — a guest, Dr. David Osser, psychiatrist treating PTSD in the VA system, at 03:47
the count holds up. two separate systematic reviews, published in 2023 and 2025, each found exactly 10 randomized placebo-controlled trials of prazosin in people with PTSD. the trials measured nightmares, insomnia, overall PTSD symptoms and, in some, alcohol use.
- overstatedPsychiatry & Psychotherapy Podcast2026-10-245 primary sources
do suicides and homicides by women peak in the days before menstruation?
“We know that both suicides and homicides peak in this days and before the cycle.” — a guest, a psychiatrist and researcher in women's mental health, at 39:04
there is a real signal behind this. a 44-study systematic review found that non-fatal suicidal behaviour clusters in the low-oestrogen phases around menstruation (late luteal and early follicular). a 1980 study of 50 women charged with violent crimes found 44% offended in the days around menstruation.
- falsePsychopharmacology and Psychiatry Updates2026-11-024 primary sources
does the va/dod ptsd guideline rate prazosin as insufficient evidence for or against?
“The VA and DOD guideline rates the evidence as insufficient for or against prazoson.” — a host, at 14:54
the wording is real. the 2017 VA/DoD PTSD guideline did say there was "insufficient evidence to recommend for or against" prazosin for nightmares associated with PTSD, and the current guideline still rates the evidence behind prazosin as low quality.
- unverifiablePsychEd: Educational Psychiatry Podcast2026-11-014 primary sources
do 91% of camh's ongoing-ect patients have no memory problems or find them worth it?
“91% of people either don't have memory problems with ongoing ECT, or if they do, they decide the side effect is worth it.” — a guest, a psychiatrist, at 56:48
camh does run an ect service with patients on ongoing (maintenance) ect, and a 2006 study from camh's own clinicians concluded that memory difficulties with maintenance ect were "limited and tolerable". published reviews also find that many people who report memory effects after ect still say they would have it again, so a figure that adds together "no memory problem" and "a memory problem I judge worth it" is not implausible.
- misattributedThe Carlat Psychiatry Podcast2026-11-022 primary sources
did people in the depression diet trial cut ultra-processed food by 85%?
“they succeeded in following it, cutting their ultra-processed foods by 85% on average.” — a host, a psychiatrist, at 15:02
the trial is real and the number is real. in a 2026 pilot crossover trial of adults with major depression, participants' mean score on an ultra-processed food screening questionnaire fell from 10.10 to 1.42, a drop of about 86%. 19 of the 20 randomized participants were analyzed, so it is fair to say most participants followed the diet, at least by their own report.
- falseHuberman Lab2026-10-224 primary sources
does 1 to 3 g of epa from fish oil improve cognition and focus?
“There's now a lot of data showing that ingesting 1 to 3 g of EPA in particular, in the form of either fish oil capsules or liquid, can be beneficial” — a host, at 27:00
The host is right that there is a large body of trials on fish-oil omega-3s, and that EPA-heavy formulas are the ones that keep showing a signal. That signal is for depressive symptoms: a 2019 meta-analysis of 26 trials found benefit from formulas that were mostly or entirely EPA.
- confirmedThe Carlat Psychiatry Podcast2026-11-023 primary sources
is an 11-point madrs gain about four times what antidepressants usually beat placebo by?
“The difference here was huge, and 11 point change on the Madras MADRS is about four times what we see with antidepressants.” — a host, a psychiatrist, at 15:23
the arithmetic holds. across 28 placebo-controlled trials of newer antidepressants that used the MADRS, drugs beat placebo by about 3 points (2.99), so an 11-point gap over placebo is about 3.7 times that. "about four times" is a fair rounding.
- misattributedThe Carlat Psychiatry Podcast2026-11-021 primary source· draft receipt
did madrs fall 11 points vs 4 when people with depression cut ultra-processed food?
“When they cut ultra-processed foods, depression fell 11 points on the clinician-rated mattress compared to four points while on their usual diet.” — a host, a psychiatrist, at 14:41
the trial is real and the speaker has the main facts right. it is a pilot crossover trial led by ucsf researchers, published in jama psychiatry on september 23, 2026, and on the madrs depression scale people did much better while cutting ultra-processed foods than on their usual diet. the gap the paper reports is about 11 points (−10.78).
- confirmedThe Carlat Psychiatry Podcast2026-11-021 primary source· draft receipt
did the ultra-processed food pilot enroll 20 depressed adults with metabolic problems?
“The researchers enrolled 20 adults with depression and at least one metabolic problem, all of whom ate large amounts of ultra-processed food” — a host, a psychiatrist, at 14:00
the description holds. the jama psychiatry pilot enrolled 20 adults, and to be eligible each one needed a primary depression diagnosis, high ultra-processed food intake and at least one self-reported metabolic abnormality.
- unverifiablePsychEd: Educational Psychiatry Podcast2026-11-014 primary sources
do 18% of ect patients at camh report memory problems, with half then stopping?
“at CAMH, the commonly quoted statistics, about 18% of people have some type of memory impairment. About half of them continue on with ECT, and half of them consider it a deal breaker.” — a guest, a psychiatrist, at 56:16
the 18% figure is in the right range. a published chart review from CAMH found that about 17% of patients (40 of 238) had cognitive impairment recorded during an acute ECT course, and a large Swedish study found subjective memory got worse in 16% of patients. the second half of the claim, that half of those patients keep going and half stop, has no published source we could find.
- overstatedPsychEd: Educational Psychiatry Podcast2026-11-014 primary sources
does dialectical behavior therapy have a 75% response rate and 30 to 40% dropout?
“The response rate is approximately 75%, but it has a 30 to 40% drop-out rate and this relates to its biggest limitation.” — a host, a psychiatry resident, at 06:19
dropout is a real and well-documented problem in dialectical behavior therapy: more than one in four people who start it in randomized trials don't finish, and routine-care programs can lose closer to 40%. a figure near 75% also exists in the literature: 77% in one outpatient study, though it covers only the people who finished and were reassessed.
- confirmedPsychEd: Educational Psychiatry Podcast2026-11-012 primary sources
did ect use in quebec fall by a third over 15 years?
“I looked at 15 years worth of data finding that ECT treatment in Quebec has dropped by about a third, 33% less ECT over the 15-year period.” — a guest, a psychiatrist, at 51:57
The number is right and so is the source. A Canadian Journal of Psychiatry study of linked Quebec health administrative data found the age-standardized rate of people receiving ECT fell from 15 to 10 per 100,000, which the authors call a 33% decrease. They describe it as "a downward trend... in the 15 y of the study."
- overstatedPsychEd: Educational Psychiatry Podcast2026-11-013 primary sources
is interpersonal psychotherapy 16 sessions focused on one of four problem areas
“It is done over 16 sessions and covers one of four interpersonal problem areas.” — a host, a psychiatry resident, at 10:04
The core description holds. Interpersonal psychotherapy is a short, time-limited treatment, 16 sessions is a standard length for it, and its formulation does tie the mood problem to one of four named areas: grief, role disputes, role transitions and interpersonal deficits.
- confirmedPsychEd: Educational Psychiatry Podcast2026-11-013 primary sources
did a 2022 lancet psychiatry study find no extra kidney decline in the first decade on lithium?
“they showed that really for that first decade, patients on lithium actually didn't have worse results than people who just had bipolar or really the general population.” — a guest, a psychiatrist, at 34:15
the study is real and says what the speaker said it says: in the 2022 lancet psychiatry paper from northern sweden, kidney function in people on lithium for up to 10 years did not decline significantly faster than in people with bipolar disorder who never took lithium or in the general population. the steeper decline showed up after more than 10 years.
- overstatedPsychEd: Educational Psychiatry Podcast2026-11-014 primary sources
does a typical course of cbt run 12 to 20 sessions?
“typically involves around 12 to 20 sessions.” — a host, a psychiatry resident, at 02:29
as a description of how a standard, manual-based course of individual cbt for depression is planned, 12 to 20 sessions is right: the u.s. department of veterans affairs' cbt-for-depression manual says a typical course is "approximately 16 sessions."
- misattributedHuberman Lab2026-10-224 primary sources
does apigenin, the chamomile compound, lower anxiety when taken as a supplement?
“also acts as a bit of a anxiety-lowering compound” — a host, at 11:18
apigenin is one of the main compounds in chamomile, and the trials do show a modest anxiety-lowering effect. in people with mild to moderate generalized anxiety disorder, a chamomile extract standardized to apigenin beat placebo, and the speaker's "a bit" fits how small that effect was.
- confirmedHuberman Lab2026-10-125 primary sources
can the dsm addiction criteria make a case for food addiction?
“if you look at the the DSM criteria for substance abuse or addiction, you can make an argument that there is food addiction based on those criterion.” — a guest, a professor of human and evolutionary biology and neurobiology, at 51:46
The speaker is right. Researchers have taken the DSM substance use disorder criteria, rewritten them for eating, and built a validated questionnaire on them. Food addiction is still not an official DSM diagnosis, and the speaker said only that "you can make an argument," which is how the literature itself frames it.
- overstatedHuberman Lab2026-09-035 primary sources
have studies of early help after trauma never looked at sleep?
“in any none of these studies has sleep ever been considered, but to me that's the key part is bringing down your sympathetic nervous system before you go to sleep” — a guest, a neuroscientist (sleep researcher), at 26:48
The speaker is right about the direction. Sleep has been a small and neglected part of research on early help after trauma. A 2022 review in a sleep-medicine journal says "few studies have evaluated treatments for acute sleep disturbances following trauma exposure", and a 2024 trial protocol calls itself the first to use digital insomnia therapy as an early trauma intervention.
- overstatedPsychiatry & Psychotherapy Podcast2026-09-264 primary sources
do women with isolated postpartum psychosis not need medication during pregnancy?
“The woman who've had isolated postpartum psychosis, they don't need it.” — a guest, a psychiatrist, at 31:25
The main research group studying this found what the speaker describes. In a cohort of 70 high-risk pregnant women, all 29 whose psychosis had only ever happened after childbirth stayed well through pregnancy with no medication. The same group's later meta-analysis endorses the matching strategy: start prevention right after delivery rather than during pregnancy, so the baby isn't exposed to medication in the womb.
- unverifiablePsychiatry & Psychotherapy Podcast2026-09-265 primary sources
have about 13 studies described the symptoms of postpartum psychosis, including cognitive ones?
“there's about 13 studies that have been, yeah, that have been completed, which describe all of the symptoms.” — a guest, a psychiatrist, at 27:12
cognitive impairment is a documented, common symptom of postpartum psychosis. a 2025 expert consensus review lists impaired cognition alongside mania, mixed states and psychotic depression, and the research base is small enough that a count in the low teens is plausible for some slice of it.
- confirmedThe Carlat Psychiatry Podcast2026-10-194 primary sources
is couple therapy in the va shorter and less effective than in the big trial? yes, roughly
“treatments in the VA tend to be short, it tends to be about 12 sessions. And so we're able to make some change, not as big a change as we did in our clinical trial” — a guest, a distinguished research professor of psychology at UCLA, at 38:41
the speaker has this right: in the va, couples get fewer sessions of integrative behavioral couple therapy than couples got in the big randomized trial, they still improve significantly, and the improvement is smaller than in the trial. a peer-reviewed review says this almost word for word.
- overstatedHuberman Lab2026-09-145 primary sources
does anorexia rewire reward so that avoiding food feels rewarding?
“one of the hallmark traits of like true anorexia is that the these reward circuits become such that the aversion of food becomes rewarding.” — a host, a neuroscientist, at 54:36
researchers do propose this. one published model of anorexia nervosa says the illness centres on the brain's striatal reward system, and that behaviour fitting the illness's goals comes to feel rewarding. brain-imaging studies do find altered reward processing in anorexia.
- overstatedThe Carlat Psychiatry Podcast2026-10-055 primary sources
does research show people with borderline personality disorder lacked marked mirroring as infants?
“Now, a lot of research showed us that people with BPD don't have those early experiences of marked mirroring.” — a guest, a clinical psychologist, at 06:28
the direction is right. studies that filmed parents with their babies and followed the children into adulthood find that disrupted early caregiving, especially a withdrawn or unresponsive parent, predicts later borderline features. "marked mirroring" is a real idea at the center of the mentalization model of borderline personality disorder.
- overstatedThe Carlat Psychiatry Podcast2026-10-054 primary sources
does better mentalizing in mbt make people stop self-harming and stop having suicidal thoughts?
“They stop self-harming, they don't have suicidal thoughts, they don't have big emotional thoughts with people or themselves and symptoms get better.” — a guest, a clinical psychologist, at 37:44
the direction is right. a 2020 cochrane review found mentalization-based treatment did better than usual care on self-harm and suicidality at the end of treatment, and people in mbt programmes do report much less self-harm over time.
- overstatedThe Carlat Psychiatry Podcast2026-10-055 primary sources
is a failure of mentalizing the core of borderline personality disorder, so fixing it treats it?
“if we're able to strengthen a patient's capacity to mentalise then you're treating the disorder essentially. That's exactly right.” — a guest, a clinical psychologist, at 08:51
people with borderline personality disorder do score far lower than healthy controls on reflective functioning, the measure most closely tied to mentalizing. one meta-analysis put the gap at d = 1.68, a very large effect. therapy built around mentalizing has also beaten usual care on self-harm and suicidality in randomized trials.
- overstatedThe Carlat Psychiatry Podcast2026-10-056 primary sources
do all people with personality disorders, or any psychopathology, struggle with mentalizing?
“It turns out that people with personality disorder, and that is across the board, all personality disorder, and in fact all people with psychotherology have difficulties in mentalizing.” — a guest, a clinical psychologist, at 03:52
the core of this holds up. people diagnosed with borderline personality disorder show measurable mentalizing problems, and pooled studies find group-level deficits in many other diagnoses too, including schizophrenia, depression, obsessive-compulsive disorder, bipolar disorder and social anxiety.
- overstatedHuberman Lab2026-09-144 primary sources
are olympic gold medalists especially likely to fall into clinical depression?
“It's why Olympic athletes are so likely to fall into a clinical depression after they win their their, you know, their gold medal.” — a guest, Arthur Brooks, professor and happiness researcher, at 55:43
the weeks and months after an olympic games are a real low point for many athletes. peer-reviewed interview studies of olympians describe a documented 'post-olympic blues', and one study of elite swimmers found a third met diagnostic criteria for depression after a major selection meet.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-282 primary sources
does the us aripiprazole label list 10 to 15 mg/day for adult schizophrenia?
“The label lists 10 to 15 milligrams per day.” — a host, at 09:53
the host is right: the US aripiprazole label lists 10 to 15 mg/day as the recommended dose for adults with schizophrenia, and the same 10 to 15 mg/day as the starting dose.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-282 primary sources
does the cariprazine label advise contraception during treatment and for 10 weeks after?
“Its manufacturer advises highly effective contraception during treatment.” — a host, at 11:01
this is right. the european product information for cariprazine says female patients who could become pregnant must use highly effective contraception during treatment and for at least 10 weeks after the last dose.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-284 primary sources
does the lurasidone label say to take it with at least 350 calories?
“Luracidone needs a meal of at least 350 calories.” — a host, at 11:09
the host has it right. the US prescribing information for lurasidone says, in its dosing section and again in its highlights, that the tablets "should be taken with food (at least 350 calories)."
- overstatedHuberman Lab2026-10-085 primary sources
does your mood on stressful days predict depression, heart disease and early death a decade later?
“for people who feel either lower negative or higher positive, they tend to have better health trajectories. So like a decade later, less depression, less heart disease, less early death.” — a guest, a stress scientist, at 18:12
the core of this is real. in u.s. daily diary studies that followed the same people for about ten years, those whose negative mood rose more on stressful days were more likely to report an anxiety or depressive disorder a decade later, and more likely to report chronic physical conditions. in one small study, people whose positive mood dropped more on stressful days were more likely to die within ten years.
- confirmedHuberman Lab2026-10-085 primary sources
do people who tolerate uncertainty have much less anxiety and depression?
“People who tolerate uncertainty have much less anxiety and depression.” — a guest, a stress scientist, at 24:42
this one holds up. across many studies, people who score higher on intolerance of uncertainty report clearly more anxiety and more depression, and the link is moderate to strong by psychology standards (correlations around 0.5), so "much less anxiety and depression" for people who tolerate uncertainty fairly describes the pattern.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-283 primary sources
does food roughly double how much ziprasidone is absorbed?
“Food can roughly double how much Zipracidone is absorbed.” — a host, at 11:13
the claim holds up. the current FDA label for ziprasidone capsules says absorption "is increased up to two-fold in the presence of food," and two manufacturer-run studies we read found exposure with a full meal at about double the fasting level.
- overstatedHuberman Lab2026-09-216 primary sources
are antidepressants overprescribed, especially in the united states?
“but but then they're overprescribed I feel like especially in the United States” — a host, at 33:24
the host is right that a large share of US antidepressant prescribing goes to people who don't meet criteria for the condition the drug is usually given for: in one national survey only 38.4% of adults whose clinician had identified depression met structured-interview criteria for major depression, and most of the rest were still on psychiatric medication. US children and teens also use antidepressants at higher rates than children and teens in the European countries that have been compared directly.
- overstatedThe Peter Attia Drive2026-08-312 primary sources
is cluster headache called the 'suicide headache' because of pain and attack frequency?
“it's also been nicknamed suicide headache not only because of the intensity of the pain but the frequency of which these attacks occur.” — a guest, a headache neurologist, at 49:53
cluster headache really is called the "suicide headache," and the name does come from how severe the pain is. the link to suicide goes back to the first clinical description in 1939. a national registry study also found that people diagnosed with the headache group that includes cluster headache died by suicide at more than twice the rate of matched comparison people.
- overstatedHuberman Lab2026-09-215 primary sources
were kids in the recent generation raised on prescribed amphetamines?
“we had a generation of kids raised on amphetamines.” — a host, at 2:15:25
millions of american children take prescription adhd medication, and amphetamine products are one of the two main stimulant families they get. in commercially insured claims, about 1 in 10 boys aged 10-14 filled a stimulant prescription in a single year.
- overstatedHuberman Lab2026-10-084 primary sources
does interval training reduce rumination, depression and anxiety?
“People feel less rumination less depression less anxiety so they're kind of tuning up the nervous system” — a guest, a stress scientist, at 10:36
the depression part holds up in some groups. In people with heart disease, and in small trials of people with mental illness, interval training lowered depressive symptoms in the trials we read.
- overstatedHuberman Lab2026-10-084 primary sources
does training people to see stress as helpful make them perform, feel and recover better?
“they have basically trained people to view stress as positive during the stressful situations. In the lab, people do better. They perform better.” — a guest, a stress scientist, at 15:12
the core is real: randomized lab studies, including ones from the lab named in the claim, find that telling people their stress arousal is useful improves performance, and a 2024 meta-analysis of 35 randomized trials (5,638 people) found a statistically significant performance benefit.
- confirmedThe Peter Attia Drive2026-08-312 primary sources
do about a third of headache-clinic patients use cannabinoids?
“about a third of our patient population are using canabonoids.” — a guest, a headache neurologist, at 57:22
the number holds. in the largest published survey of patients at a tertiary headache center, 32.5% of respondents said they were currently using cannabis-based products, so "about a third" is accurate.
- confirmedLex Fridman Podcast2026-09-213 primary sources
is the evidence that cbt works for schizophrenia poor?
“If I look at the literature on CBT, for example, and its uses in cases of schizophrenia, the evidence is pretty poor that it works.” — a guest, a historian of psychiatry, at 08:54
the speaker's description holds up. the literature's own quality grades rate the evidence for CBT in schizophrenia as weak to low certainty, and the effects it finds are small. they get smaller still when the people scoring symptoms don't know who got CBT.
- overstatedThe Diary of a CEO2026-10-152 primary sources
are about 25% of people genetically early chronotypes and 16% late ones?
“that is about, by the way, 25% of the human population.” — a guest, a cognitive neuroscientist, at 1:41:57
the numbers are in the right range. in the largest chronotype dataset we read, 23.9% of about 450,000 uk adults called themselves "definitely a morning person". a us time-use study put 16% of people in its "late" chronotype group and found that a quarter of people sleep noticeably earlier than the rest. chronotype is also partly inherited, and hundreds of gene variants are linked to it.
- unverifiableThe Diary of a CEO2026-10-152 primary sources
did grayscale phones cut daily use by an hour? the study isn't public
“we saw on average people spent 1 hour less on their phones every single day.” — a guest, a cognitive neuroscientist, at 46:34
grayscale mode does cut phone use in controlled studies. published trials we read found daily screen time went down when phones were set to grayscale, so the direction of the claim matches the record.
- overstatedThe Peter Attia Drive2026-10-264 primary sources
do people with major depression have dysregulated cortisol?
“major depression has people have cortisol dysregulation” — a guest, a psychologist and neuroscientist, at 54:32
on average, people with major depression do show more cortisol and more hpa-axis activity than people without it. four decades of studies point the same way, and the gap is largest in older inpatients and in melancholic or psychotic depression.
- overstatedLex Fridman Podcast2026-09-214 primary sources
is psychoanalysis now a niche treatment only the very wealthy can afford?
“it's become a niche product now. Only only the very wealthy can afford to do it” — a guest, a historian of psychiatry, at 01:47
in the united states, open-ended, several-times-a-week psychoanalysis costs a lot, and much of it falls on the patient. private therapists charge about $143 a session in cash, and about a third of them don't take insurance at all. at that rate a few hundred sessions adds up to tens of thousands of dollars.
- confirmedThe Carlat Psychiatry Podcast2026-10-261 primary source· draft receipt
did each year of adhd medication use go with a 4% rise in cardiovascular risk in a swedish study
“each year of ADHD medication use bumped up cardiovascular risk by 4%.” — a host, a psychiatrist, at 01:49
the number is right. a swedish nested case-control study in jama psychiatry reported that each additional year of cumulative adhd medication use was associated with a 4% higher risk of cardiovascular disease (adjusted odds ratio 1.04, 95% ci 1.03-1.05).
- misattributedThe Peter Attia Drive2026-10-264 primary sources
do 70% of people without complicated grief recover on their own?
“I would say the evidence is something like 70% of people who don't experience complicated grief,” — a guest, a psychologist and neuroscientist, at 2:28:00
the number is real. in the bereavement-trajectory research the speaker named, about two-thirds of bereaved people follow a "resilient" course with little or no lasting rise in symptoms: 66.3% of 301 older adults who lost a spouse, and 65.7% on average across 54 trajectory studies of loss and potential trauma.
- misattributedThe Peter Attia Drive2026-10-265 primary sources
does ordinary grief fade in a couple of months, and complicated grief in a year or two?
“I think it's like a couple of months and then complicated grief like loss of a child or something can go on for for longer” — a guest, a psychologist and neuroscientist, at 2:28:24
the outline is right. most bereaved people do not develop a lasting disorder, and grief after losses like the death of a child can go on much longer than ordinary grief. that is what the research the speaker named found, and it is how current diagnostic manuals define prolonged grief.
- misattributedThe Carlat Psychiatry Podcast2026-10-261 primary source· draft receipt
did a swedish study find stimulant users had 25% higher cardiovascular risk by year five?
“By year five, stimulant users had a 25% increase in risk compared to those not on ADHD medications.” — a host, a psychiatrist, at 02:04
the swedish study exists and the number is real: people with adhd who had taken adhd medication for 3 to 5 years had about 27% higher odds of a new cardiovascular diagnosis than people with adhd who took none, and about 23% higher after more than 5 years. "about 25% by year five" is a fair rounding of those two figures.
- falsePsychopharmacology and Psychiatry Updates2026-10-234 primary sources
is there no evidence that antipsychotics help ocd when added early to an ssri?
“there's no evidence that second-generation anti-psychotics had any benefit at all early on in OCD treatment.” — a guest, Dr. Robert Hudak, professor of psychiatry at the University of Pittsburgh, at 02:30
most of the trial evidence for adding a second-generation antipsychotic to an ssri in ocd comes from people who had already failed an adequate ssri trial, and the standard advice is to give the ssri about three months before adding anything. the one early trial of olanzapine, added after only eight weeks of fluoxetine, found no extra benefit.
- undersoldPsychiatry & Psychotherapy Podcast2026-10-242 primary sources
are almost one in five older women taking an antidepressant?
“We also know that, you know, especially among older women, the use of as-rise sky high. I think it's almost one out of five women being on the” — a guest, a psychiatrist and researcher in women's mental health, at 44:11
the speaker is right that antidepressant use is common among older women in the us and has been rising. the federal survey data put it at about one in five women in midlife and closer to one in four women aged 60 and over.
- overstatedThe Carlat Psychiatry Podcast2026-10-195 primary sources
have more than 5,000 couples gone through the online couple therapy program in randomized trials?
“Over 5,000 couples have gone through it as part of randomized clinical trials. So it's been supported by federal research for 15 years.” — a guest, a distinguished research professor of psychology at UCLA, at 42:13
the program is real, it is an online adaptation of integrative behavioral couple therapy, it has been tested in several randomized trials, and those trials were paid for by federal grants from the national institute of child health and human development and the administration for children and families.
- confirmedThe Peter Attia Drive2026-10-054 primary sources
are postpartum blues really common in the first two weeks after birth?
“So so postpartum blues are really common like having dramatic changes in the mood.” — a guest, an obstetrician (maternal-fetal medicine physician-scientist), at 33:36
the speaker is right. postpartum blues are common, they show up in the first days after birth, and they clear within about two weeks. the studies we read put the share of new mothers affected at roughly a quarter to two-fifths, and a pooled estimate puts it at 39%.
- overstatedLex Fridman Podcast2026-09-214 primary sources
has psychiatric research money gone almost all to drugs, neuroscience and genetics?
“We have spent all our monies on drugs, on neuroscience, and on genetics.” — a guest, a historian of psychiatry, at 00:37
the speaker has the main point right for the largest public funder of psychiatric research. a 2016 editorial by a group of psychiatric researchers in the british journal of psychiatry reported that since 2012 only about 15% of the US national institute of mental health budget went to services and interventions research (HIV/AIDS excluded), with the other 85% going to basic and translational neuroscience.
- overstatedPsychiatry & Psychotherapy Podcast2026-10-242 primary sources
did a uk biobank study find a peak in bipolar disorder onset around perimenopause?
“there is a new UK bio-bank study, or not, that new, it's last year or so, showing that for bipolar disorder, it has a bit of a peak” — a guest, a psychiatrist and researcher in women's mental health, at 33:02
the study is real and says what the speaker remembered: in 128,294 UK Biobank women, first onsets of mania/bipolar disorder were about twice as common in the four years around the final period as in the late reproductive years, then fell back after menopause. the only part that doesn't hold up is the date. the paper came out in august 2024, about two years before the episode, not "last year or so", and the speaker flagged that themselves ("or not, that new").
- confirmedPsychopharmacology and Psychiatry Updates2026-10-233 primary sources
is aripiprazole fda approved for ocd? no, and the label shows it
“Our epiprozole, for example, is not FDA approved for OCD.” — a host, at 01:24
the host is right: aripiprazole is not FDA approved for obsessive-compulsive disorder. ocd is not among the indications on the reference prescribing information for the oral tablets, or on a current generic oral label.
- overstatedThe Carlat Psychiatry Podcast2026-10-195 primary sources
did couple therapy gains last two years, with only a little loss by five?
“We gave them 26 sessions over about six to eight months and that showed effectiveness that last step for a full two year follow-up. There was a little bit of loss over five years.” — a guest, a distinguished research professor of psychology at UCLA, at 38:10
most of this checks out. the trial is real and it did follow 134 seriously and chronically distressed married couples for five years with no more treatment. about 8 months of therapy left 69% of the couples in the integrative arm clinically improved two years later, and average satisfaction at five years was still well above where couples started.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-233 primary sources
do a little over two in 100 adults meet criteria for ocd at some point in life?
“A little over two in 100 adults meet criteria at some point in life.” — a host, at 01:15
the number holds up. the main us national survey put lifetime ocd among adults at 2.3%, which is "a little over two in 100", and nimh publishes that same figure today.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-232 primary sources
does the risperidone label for adult schizophrenia go up to 16 mg a day?
“Its label for adult schizophrenia goes as high as 16 milligrams a day.” — a host, at 08:41
the number is right. the current risperidone prescribing information lists the effective dose range for adults with schizophrenia as 4 to 16 mg a day, so 16 mg is the top of the range the label prints.
- misattributedPsychiatry & Psychotherapy Podcast2026-10-243 primary sources
did forgetfulness go from 31% to 44% to 41% across menopause in a study of 16,000 women?
“in one study of 16,000 women, forgetfulness complaints rose from 31%, before menopause, to 44%, in early, perimenopause, then stayed at 41%, after perimenopause.” — a host, at 47:49
the study is real: the 1995–97 baseline survey of the Study of Women's Health Across the Nation (SWAN) enrolled 16,065 women aged 40–55. the 31% premenopausal and 44% perimenopausal forgetfulness figures match published reviews of that survey, and so does the main point that forgetfulness complaints are more common in perimenopause than before it.
- unverifiableThe Carlat Psychiatry Podcast2026-10-195 primary sources
has the va used integrative behavioral couple therapy as its couple treatment for 16 years?
“For the last 16 years, the US Department of Veterans Affairs, which is the largest provider of healthcare in the country, has adopted IVCT as its evidence-based treatment.” — a guest, a distinguished research professor of psychology at UCLA, at 40:25
the VA does use integrative behavioral couple therapy as its evidence-based couple therapy and trains clinicians in it across the whole system; a 2025 VA document calls it "the evidence-based protocol for couple therapy currently used" in the veterans health administration. VA also describes its health system as the largest integrated health care system in the US.
- overstatedPsychiatry & Psychotherapy Podcast2026-09-263 primary sources
is anti-nmda receptor encephalitis behind two to four percent of postpartum psychosis?
“anti-NMDA, which is about two to four percent, but it's a small amount” — a guest, a psychiatrist, at 16:24
the speaker has the size of it right: anti-NMDA receptor encephalitis explains only a small share of postpartum psychosis. the low end of the range, about two percent, matches the one systematic screening study we found.
- overstatedPsychiatry & Psychotherapy Podcast2026-09-183 primary sources
do fewer than 20% of us bipolar patients get lithium, versus over half elsewhere?
“in the US, like less than 20% gets lithium, whereas in the rest of the world, more than half of the bipolar patients get lithium.” — a guest, a psychiatrist and director of a women's mental health center, at 31:11
The US half of this checks out. US office-visit data show lithium in roughly 14 to 17% of bipolar care since the late 2000s, and US use does trail Europe's and Asia's.
- undersoldPsychopharmacology and Psychiatry Updates2026-10-145 primary sources
is ocd about twice as common as schizophrenia? more like three to six times
“That makes it about twice as common as schizophrenia.” — a host, at 01:16
the direction is right: by every primary estimate we read, more people have OCD over their lifetime than have schizophrenia. "twice as common" is the cautious version of what the record shows, not the inflated one.
- unverifiablePsychiatry & Psychotherapy Podcast2026-09-184 primary sources
is postpartum depression about twice as likely to be bipolar as depression at other times?
“depression's occurring in the postpartum period are more often bipolar depression than depression's at other times, that is an old ratio of two.” — a guest, a psychiatrist and director of a women's mental health center, at 21:46
the direction is right. a first psychiatric episode that starts soon after childbirth is followed by a bipolar diagnosis more often than an episode that starts at other times, and three separate lines of research we read point the same way.
- confirmedPsychiatry & Psychotherapy Podcast2026-09-183 primary sources
do about 98% of women with postpartum psychosis reach full remission?
“So postpartum psychosis like amazing, like 98% gets fully better as in really our criteria for getting better or strict.” — a guest, a psychiatrist and director of a women's mental health center, at 13:45
The number is real. In a cohort of 64 women admitted for postpartum psychosis, 98.4% reached complete remission, defined as no psychotic, manic or severe depressive symptoms for at least a week. The paper ran in the American Journal of Psychiatry.
- overstatedHuberman Lab2026-09-035 primary sources
does talking about a trauma right afterward make things worse?
“one of the things that people thought might help after a trauma like a school shooting or whatever you know car accident is to talk about it and in but in fact that ended up being counterproductive.” — a guest, a neuroscientist (sleep researcher), at 26:15
the speaker is right that the structured single-session debriefing used after disasters and accidents in the 1980s and 1990s did not prevent ptsd, and that in some trials people who got it did worse than people who didn't. that includes a car-crash trial in which the debriefed group was worse off three years later.
- overstatedHuberman Lab2026-09-142 primary sources
is anorexia the most deadly psychiatric disorder?
“it's the most deadly of the psychiatric disorders.” — a host, a neuroscientist, at 55:13
anorexia nervosa does carry one of the highest mortality risks in psychiatry. people with it die at roughly six times the expected rate, and outside the substance use disorders, no condition in the main mortality meta-review ranks higher.
- overstatedPsychEd: Educational Psychiatry Podcast2026-09-013 primary sources
do two-thirds of homeless people have a mental illness, and two-thirds a substance use disorder?
“about two-thirds of the homeless population has a current diagnosable mental illness and about the same percentage have a current substance use disorder.” — a guest, a psychiatrist and senior scientist at CAMH, at 07:00
the first half holds. the largest global meta-analysis puts current mental disorder among people experiencing homelessness at 67%, which is two-thirds, and a high-income-country meta-analysis puts it higher, at 76%.
- overstatedPsychEd: Educational Psychiatry Podcast2026-09-014 primary sources
did housing first beat usual care in canada's at home/chez soi trial, especially for high needs?
“Housing first works much better than used well care especially for those that have the highest support needs those that have a primary psychologicalness.” — a guest, a psychiatrist and senior scientist at CAMH, at 25:58
the housing part holds up, and the gap is big. across the five cities, high-needs participants given housing first with assertive community treatment spent 71% of their time stably housed over two years, against 29% for usual care. the one long follow-up, which covers only the toronto site, found the advantage lasting six years and larger for high-needs participants than for moderate-needs participants.
- overstatedPsychEd: Educational Psychiatry Podcast2026-09-012 primary sources
did housing first participants still do better than usual care seven years later?
“Even seven years later those that were in the house and first did so much better than those that got usual care” — a guest, a psychiatrist and senior scientist at CAMH, at 26:23
the core of this is true. in the toronto arm of the at home/chez soi trial, people randomized to housing first were still stably housed on more days than the usual-care group six years in, and the gap was largest for people with high support needs.
- confirmedPsychEd: Educational Psychiatry Podcast2026-09-014 primary sources
do housing first trials show better housing but not better symptoms or substance use?
“We have an necessarily seen improvements in all outcomes with housing first such as consistent improvement in mental health symptoms or substance use health issues” — a guest, a psychiatrist and senior scientist at CAMH, at 30:53
The speaker's claim holds up. In the randomized trials, Housing First keeps people housed for far more days than usual care. Mental health symptoms and substance use are not consistently better than in usual care, and in the largest Canadian trial they were no better on any measure.
- unverifiablePsychiatry & Psychotherapy Podcast2026-09-185 primary sources
did about half of women without lithium relapse within a year after a postpartum psychosis?
“the women without lithium, we saw unfortunately that half of them relapsed within a year after delivery.” — a guest, a psychiatrist and director of a women's mental health center, at 25:34
the speaker's group has published this kind of finding. in their 2012 cohort, 44.4% of women with a history of postpartum-only psychosis who declined postpartum prophylaxis relapsed after delivery, while none of the 20 who took it did. that is close to "about half."
- confirmedLex Fridman Podcast2026-09-205 primary sources
is the evidence that cbt works for schizophrenia poor?
“If I look at the literature on CBT, for example, and its uses in cases of schizophrenia, the evidence is pretty poor that it works.” — a guest, historian of psychiatry (Andrew Scull), at 17:19
the speaker is right on the main point. pooled trials of cbt for schizophrenia find small effects, the effects shrink toward zero when outcome raters are blinded, and independent reviews rate the certainty of the evidence low or very low.
- overstatedLex Fridman Podcast2026-09-203 primary sources
for mild depression, does cbt work better than antidepressants, with fewer side effects?
“for the milder forms of depression, I think CBT works better than the drugs without some of the side effects that the the drugs have.” — a guest, historian of psychiatry (Andrew Scull), at 18:03
antidepressants add little over placebo for milder depression, and they carry side effects that talking therapy does not. people also drop out of psychotherapy less often than out of drug treatment, and the benefit of psychotherapy holds up better at 6–12 months.
- overstatedLex Fridman Podcast2026-09-205 primary sources
does clozapine work better than other antipsychotics in treatment-resistant schizophrenia?
“it tends to it turns out it tends to work better in treatment-resistant cases, meaning cases don't respond to the other um antipsychotics that we have” — a guest, a historian of psychiatry (Andrew Scull), at 16:25
clozapine is the one antipsychotic with randomized evidence built specifically around people whose schizophrenia did not respond to other antipsychotics. in the trial behind its approval, 30% of treatment-resistant patients responded on clozapine against 4% on chlorpromazine, and it still beats first-generation drugs like haloperidol in pooled data.
- confirmedLex Fridman Podcast2026-09-206 primary sources
does cochrane rate the evidence for cbt as at best low to moderate certainty?
“The Cochrane reviews, which are a systematic attempt to assess how strong the evidence for particular approaches to disease of all sorts are say that at best the evidence for CBT is of low and medium confidence, you know?” — a guest, historian of psychiatry (Andrew Scull), at 17:37
The speaker has this right. In every Cochrane review of cognitive behavioral therapy we opened, the best evidence was rated moderate (Cochrane's word for what the speaker called "medium"). Most outcomes were rated low or very low, and none were rated high.
- confirmedThe Carlat Psychiatry Podcast2026-09-282 primary sources
did a 2026 study report a clinic cutting psychiatry waits from 10 months to six weeks?
“how did a community clinic reduce wait times for new psychiatric appointments from 10 months to six weeks?” — a host, a psychiatrist, at 00:55
the study is real and says it: a 2026 quality improvement paper from a Canadian community hospital's outpatient psychiatry service reports average wait times falling from about 10 months to about 6 weeks after it started structured triage and phone consults with family doctors.
- overstatedLex Fridman Podcast2026-09-204 primary sources
does fda approval need only two winning trials, no matter how many failed?
“to get FDA approval of efficacy and safety, you needed two trials. You might have conducted 15 trials and 13 of them had been failures, but if you had two that worked, that was enough.” — a guest, a historian of psychiatry (Andrew Scull), at 18:19
The speaker is right about the old rule. For decades the FDA's stated position was that the 1962 law required "at least two adequate and well-controlled studies, each convincing on its own." The speaker is also right that drugs have been approved even though many of their trials failed. FDA reviews of antidepressant approvals show about half of the submitted placebo-controlled trials came out positive.
- confirmedHuberman Lab2026-09-213 primary sources
do adhd stimulants like amphetamine slow children's growth and affect sleep?
“it's remarkable but they're worried about the reduced uh growth effects.” — a host, at 2:14:53
both halves of the claim hold up. the current fda label for an extended-release amphetamine product says stimulants slow growth in children and lists insomnia as one of the most common side effects. the largest long-term study we found ties years of stimulant use to shorter adult height.
- overstatedPsychEd: Educational Psychiatry Podcast2026-10-013 primary sources
does bupropion carry a substantial seizure risk in anorexia and bulimia, and is it the electrolytes?
“adding buropropion on top of that carries a substantial risk of seizure.” — a host, a psychiatry resident, at 12:40
the core of this is right. bupropion carries an FDA contraindication for anyone with a current or past diagnosis of bulimia or anorexia nervosa because seizures were seen more often in these patients, and the trial that started it saw four grand mal seizures in a bupropion arm of 55 people with bulimia, a rate well above anything seen in earlier studies of the drug.
- overstatedPsychopharmacology and Psychiatry Updates2026-09-234 primary sources
is paliperidone the antipsychotic most likely to raise prolactin, with others in the middle?
“pelliparidone, which is probably the worst offender, then you have in the middle a lens of pain, a le residone, a certain pain and a suppressorone” — a guest, a professor of psychiatry at Harvard Medical School, at 05:20
the headline point holds: in the largest network meta-analysis of oral antipsychotics, paliperidone raised prolactin more than any of the 32 drugs compared, and its us label says the same thing in plainer words. olanzapine, asenapine and sertindole also raised prolactin significantly in that analysis, at levels below the top group.
- confirmedPsychEd: Educational Psychiatry Podcast2026-10-015 primary sources
are a bmi under 16, under 75% of expected weight, and rapid weight loss refeeding risks?
“Less than 75% of expected body weight or BMI under 16 in adults, rapid or prolonged weight loss, even from a higher starting point.” — a host, a psychiatry resident, at 11:38
The risk factors the resident listed are the ones the main refeeding guidance uses. A BMI under 16 puts an adult in the top risk tier under both the UK NICE criteria and the 2020 ASPEN consensus. Recent weight loss counts on its own, whatever the person's starting weight.
- confirmedPsychopharmacology and Psychiatry Updates2026-09-235 primary sources
do risperidone and all first-generation antipsychotics reliably raise prolactin?
“resparidone itself and all the first generation antipsychotics reliably cause hyperpolectenemia” — a guest, a professor of psychiatry at Harvard Medical School, at 05:13
this one holds up. risperidone raises prolactin in most people who take it, and first-generation antipsychotics raise it as a class. the FDA labels and the trial literature both say so.
- overstatedPsychopharmacology and Psychiatry Updates2026-09-234 primary sources
are sexual side effects one of the most common reasons young people stop antipsychotics?
“sexual side effects are one of the most common reasons that young people stop taking antipsychotics.” — a host, a clinician educator, at 00:29
sexual side effects do push young people off antipsychotics. in a london cohort of 2,309 people with first-episode psychosis (mean age 26.7), people whose records noted sexual dysfunction stopped their first antipsychotic sooner (hazard ratio 1.59). sexual problems are also common and distressing, and they are underreported.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-184 primary sources
did the fda add a boxed warning on complex sleep behaviors to the z-drugs in 2019?
“In 2019, the FDA added a boxed warning to this class.” — a host, at 01:58
this one holds up. in 2019 the fda required a boxed warning about complex sleep behaviors (sleepwalking, sleep-driving and doing other things while not fully awake) on all three z-drugs: zolpidem, eszopiclone and zaleplon.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-181 primary source· draft receipt
did a jama psychiatry study analyze insurance claims from over 4 million pregnancies?
“The researchers analyzed insurance claims from over 4 million pregnancies.” — a host, at 01:03
the number holds up. the 2024 JAMA Psychiatry cohort study of prescription stimulants in pregnancy drew on Medicaid and MarketScan claims data, and it covered about 4.3 million pregnancies, comfortably over 4 million.
- overstatedLex Fridman Podcast2026-09-214 primary sources
did nice conclude cbt beats antidepressants for milder depression, with fewer side effects?
“nice, which is the British organization that passes on what treatments the National Health Service will support and which ones are uh sufficiently evidence-based, um has come to that same conclusion.” — a guest, a historian of psychiatry, at 09:51
this part is true: NICE's 2022 adult depression guideline moved antidepressants down for less severe depression. it says they should not routinely be offered first-line unless that is the person's preference, and it places CBT and behavioural activation among its top-ranked first-line options.
- confirmedHuberman Lab2026-09-214 primary sources
is the united states the biggest consumer of prescription drugs in the world?
“aren't we the biggest consumer of prescription drugs in the whole world?” — a host, at 33:33
measured in money, yes. in 2022 the united states accounted for 62.4 percent of all prescription drug sales across 34 wealthy countries, more than the other 33 combined, and its market is more than three times the size of the next-largest country's, china's.
- unverifiablePsychopharmacology and Psychiatry Updates2026-10-182 primary sources
was the major malformation rate about 4% after first-trimester z-drug exposure in both data sets?
“In both data sets, the rate of any major congenital malformation was 4% after an exposure” — a guest, Dr. Amanda Corrier, presenting for the Psychopharmacology Institute, at 05:17
the study is real and says what the speaker says it says on the question that matters: in a JAMA Psychiatry cohort of 4.3 million pregnancies drawn from Medicaid and MarketScan insurance claims, first-trimester z-drug exposure was not linked to more major congenital malformations after adjustment (pooled relative risk 1.01, 95% CI 0.95-1.08).
- confirmedPsychopharmacology and Psychiatry Updates2026-10-183 primary sources
was zolpidem fda approved in 1992 for short-term treatment of insomnia? yes
“It was FDA approved in 1992 for short-term treatment of insomnia.” — a host, at 01:45
The claim holds as stated. The FDA approval record shows zolpidem was first approved on december 16, 1992, and every FDA label we read gives "short-term treatment of insomnia" as its indication.
- overstatedThe Peter Attia Drive2026-08-313 primary sources
are amitriptyline and nortriptyline rarely used for depression, at much lower migraine doses?
“if we're using a medication like amatrippleene and norripane often the doses we're using are much lower than what would be needed to treat depression and rarely are these medications used to treat depression anymore.” — a guest, a headache neurologist, at 19:45
the first half holds up where we could measure it: in a large canadian primary-care sample, tricyclics made up 2.7% of antidepressant prescriptions written for depression, and the main use of amitriptyline was pain, not mood. low doses such as 10–25 mg a day do show up in migraine trials, and those sit well below the 75–150 mg a day the us label gives for depression.
- confirmedLex Fridman Podcast2026-09-216 primary sources
do cochrane reviews rate the evidence for cbt as low or moderate certainty at best?
“The Cochrane reviews, which are systematic attempt to assess how strong the evidence for particular approaches to disease of all sorts are, say that at best the evidence for CBT is of low or medium confidence” — a guest, a historian of psychiatry, at 09:13
the speaker is right about the cochrane reviews we read. across five cochrane reviews of cbt, covering anxiety in children, anxiety in older adults, chronic pain, tinnitus and insomnia in cancer, nothing was rated high certainty. the best rating anywhere was moderate, and most outcomes were low or very low.
- confirmedThe Peter Attia Drive2026-08-315 primary sources
do depression and anxiety travel with migraine, in both directions?
“person's mood depression anxiety are comorbid with migraine right they coexist at a higher than expected by chance and there's birectional relationship between mood disorders and migraine.” — a guest, a headache neurologist, at 58:00
the neurologist is right on both counts as an epidemiologist would mean them: people with migraine have roughly double the odds of depression and anxiety, and in a community cohort followed over time, each condition predicted new onset of the other.
- confirmedLex Fridman Podcast2026-09-214 primary sources
are most antidepressants prescribed by primary care doctors, not psychiatrists?
“many of these things, particularly antidepressants, are dispensed by primary care docs, not not psychiatrists.” — a guest, a historian of psychiatry (Andrew Scull), at 12:39
this one holds up. in the national survey data we read, about three in four us adults taking an antidepressant got it from a general medical provider, not a psychiatrist.
- overstatedLex Fridman Podcast2026-09-223 primary sources
were there about 300 psychoanalysts in north america around 1930
“circa 1930 there are probably 300 psychoanalysts in North America.” — a guest, at 29:54
the speaker is right that psychoanalysis was a very small profession in north america around 1930. it was a few hundred people at most, not thousands. the institutes, training standards and journals that later made it dominant were only being built during that decade.
- confirmedLex Fridman Podcast2026-09-224 primary sources
did an american neurologist develop the rest cure, aimed mainly at women?
“something called the rest cure which Silas we Mitchell one of the leading lights of American neurology developed” — a guest, at 06:48
the speaker has this right. the peer-reviewed historical literature credits the rest cure to the philadelphia physician the speaker named. it describes him as an american neurologist, and medical writers call him the "father of american neurology". the regime was close to what the claim sentence describes: weeks of strict bed rest, isolation, forced heavy feeding and no reading. it was mostly applied to women.
- overstatedLex Fridman Podcast2026-09-215 primary sources
does cbt beat antidepressants for mild depression, with fewer side effects?
“for the milder forms of depression, I think CBT works better than the drugs without some of the side effects that the the drugs have.” — a guest, a historian of psychiatry, at 09:39
for milder depression the record does back two things: antidepressants barely beat a sugar pill, and cbt works about as well as the drugs while avoiding drug side effects like nausea and sexual problems. the speaker was right that there is no case for drugs being the better first choice for milder depression.
- overstatedLex Fridman Podcast2026-09-214 primary sources
did major drug companies abandon psychiatric drug research?
“the fact that major drug companies have abandoned research in this area” — a guest, a historian of psychiatry, at 04:28
it's true that some of the largest drug companies pulled back hard from psychiatric drug research around 2010 to 2013. one closed its psychiatric labs entirely, another shut down its in-house psychiatric research, and a third cut its programs sharply. the federal mental-health research agency's own leadership called it a crisis at the time.
- confirmedLex Fridman Podcast2026-09-214 primary sources
did remote therapy rise during covid when in-person visits stopped?
“We did see the rise of some of this distant learning of this” — a guest, a historian of psychiatry, at 02:47
the speaker is right: once in-person visits collapsed in spring 2020, mental health care moved to remote delivery. three separate us claims datasets and a survey of therapists all show it.
- unverifiablePsychopharmacology and Psychiatry Updates2026-10-143 primary sources
did 35% on memantine vs 7.1% of controls rate very much improved in a 44-patient ocd study?
“So 35% of the MEMINTINE group were related is very much improved. Only 7.1% of control subjects were related is improved.” — a guest, a professor of psychiatry at the University of Pittsburgh, at 04:04
the study is real and the design matches the description: a single-blind case-control study of 44 patients with severe ocd in the mclean/massachusetts general hospital intensive residential treatment program, 22 of whom also got memantine. global improvement was measured on the clinical global impression scale, and every outcome we could read favored the memantine group.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-144 primary sources
is the worldwide lifetime prevalence of ocd roughly 1% to just over 2%?
“Its worldwide lifetime prevalence is roughly 1 to just over 2%.” — a host, at 01:11
the range the host gave matches the main record. a meta-analysis of 34 community studies from around the world puts lifetime OCD prevalence at 1.3%, and the large US national surveys put it at 2.3%. "roughly 1 to just over 2%" covers both.
- confirmedPsychiatry & Psychotherapy Podcast2026-09-262 primary sources
did a study find 53% of women with postpartum psychosis have delusions about the infant?
“Chandra, at all saying that the majority of women with postpartum psychosis, 53% have delusional ideas that are related to the infant specifically.” — a host, a psychiatrist, at 54:13
the number is real and the attribution is right: a 2006 study by Chandra and colleagues reported that 53% of 108 women hospitalized with severe mental illness beginning after childbirth had delusions related to the infant.
- unverifiablePsychopharmacology and Psychiatry Updates2026-10-143 primary sources
did riluzole beat placebo for treatment-resistant ocd in children? no, and the numbers mostly hold
“The Y-box and the Real ESAW group decreased from 27 to a little under 22.” — a guest, a professor of psychiatry at the University of Pittsburgh, at 07:52
the trial is real and the core of the claim holds: a 12-week, double-blind, placebo-controlled trial of add-on riluzole in 60 treatment-resistant children and teens with OCD found that both groups improved and there was no significant difference between riluzole and placebo. the riluzole group's endpoint score of a little under 22 matches the registered result (21.72).
- confirmedPsychopharmacology and Psychiatry Updates2026-10-093 primary sources
did the sino trial randomize over 3,000 inpatients aged 18 to 45 at 32 hospitals in china?
“It enrolled over 3000 hospitalized patients from 32 hospitals across China. Patients were 18 to 45 years old.” — a host, at 01:19
every number in the sentence holds up. the published trial randomized 3,067 inpatients aged 18 to 45 with acutely ill schizophrenia at 32 hospitals, and companion papers on the same cohort place those hospitals in China.
- confirmedLex Fridman Podcast2026-09-223 primary sources
were there hundreds of thousands of patients in us mental hospitals around 1930?
“they can't treat that many patients a few thousand when there are hundreds of thousands in the hospitals” — a guest, at 30:10
the speaker is right. around 1930, us mental hospitals held a few hundred thousand patients. the census bureau's own series puts it at about 353,000 at the end of 1931 and about 445,000 by 1940.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-092 primary sources
is the labeled adult aripiprazole dose for schizophrenia 10-15 mg a day, with a 30 mg maximum
“The labeled adult dose for schizophrenia is 10-15 mg a day. The maximum is 30 mg a day.” — a host, at 13:52
the host has it right. the current FDA-approved labeling for oral aripiprazole lists 10 to 15 mg/day as both the starting and recommended dose for adults with schizophrenia, and 30 mg/day as the maximum.
- confirmedThe Carlat Psychiatry Podcast2026-10-122 primary sources
did each point of baseline ocd severity cut the odds of ssri response by about 8%?
“every one point increase in baseline severity lowered the odds of response by about 8%.” — a host, a psychiatrist, at 05:10
the number is right and it is the paper's own number. a 2025 individual-participant meta-analysis of placebo-controlled ssri trials in children and adolescents with ocd reports that for each one-point increase in baseline cy-bocs, the odds of being a responder fell by 8% in the treatment group relative to the placebo group.
- confirmedThe Carlat Psychiatry Podcast2026-10-123 primary sources
did a 2025 study pool four trials of more than 600 kids aged 6 to 18 with ocd? yes
“a 2025 study by Cohen and colleagues who'll data from four randomized controlled trials involving more than 600 children and adolescents, ages 6 to 18 with OCD.” — a host, a psychiatrist, at 02:22
The description holds. The 2025 Cohen et al. paper is an individual participant data meta-analysis of four randomized, placebo-controlled trials of SSRIs for pediatric OCD. It covers 614 patients, and the authors split them into age bands of 6 to 11 and 12 to 18.
- unverifiablePsychopharmacology and Psychiatry Updates2026-10-094 primary sources
did aripiprazole have the lowest sedation rate, 4%, of seven antipsychotics in the sino trial?
“aeropipersol only had four percent sedation. The lowest of all anti-psychotics, which is truly a novel finding that had not been reported previously using a good measure of sedation.” — a guest, a psychiatrist (co-director of the MGH Psychosis Clinical and Research program), at 07:58
the main point holds: in the SINO trial, which randomized 3,067 inpatients to one of seven antipsychotics, the published abstract says aripiprazole was the least sedating, with relative risks of 0.30 to 0.39 against each of the other six drugs. what we could not check is the specific 4% figure, because it is not in the abstract and the full paper was closed to us.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-091 primary source· draft receipt
did haloperidol cause the most movement side effects of seven antipsychotics in the sino trial
“Hello Paridol had the highest rate of extra pyramidal symptoms of all anti-psychotics, including when directly compared with Prefenisine.” — a guest, a psychiatrist (co-director of the MGH Psychosis Clinical and Research program), at 07:44
the trial exists and the abstract supports the claim. In a 32-hospital randomized trial of seven antipsychotics in 3,067 acutely ill adults with schizophrenia, the authors report that "haloperidol was associated with a higher risk of extrapyramidal symptoms than all other drugs," and the other drugs include perphenazine, the other first-generation drug in the trial.
- overstatedThe Carlat Psychiatry Podcast2026-10-122 primary sources
were kids on ssris nearly twice as likely to respond in the 2025 pediatric ocd meta-analysis?
“kids taking SSRIs turned out to be nearly twice as likely to achieve a treatment response, which they define as at least a 35% reduction in symptoms.” — a host, a psychiatrist, at 04:04
the study is real and was described correctly: a 2025 meta-analysis of individual participant data in the journal of the american academy of child and adolescent psychiatry defined response as a reduction of at least 35% on the children's yale-brown obsessive-compulsive scale (cy-bocs), and found a response odds ratio of 1.89 in favor of ssris over placebo. "nearly twice" is a fair reading of 1.89.
- falseHuberman Lab2026-09-145 primary sources
did about 100,000 people in the us die of opioid overdoses last year?
“100,000 people died of, you know, opiate overdoses or something last year.” — a guest, Arthur Brooks, professor and happiness researcher, at 2:31:04
the 100,000 figure is real: cdc's final counts show more than 100,000 us drug overdose deaths in each of 2021, 2022 and 2023 (106,699, 107,941 and 105,007), and opioids were involved in roughly three out of four of them.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-033 primary sources
did fluvoxamine get fda approval for ocd in 1994?
“Fluvoxamine received FDA approval for OCD in 1994.” — a host, at 01:27
the host has it right: the FDA first approved fluvoxamine on december 5, 1994, and the indication it was approved for, then and now, is obsessive-compulsive disorder.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-033 primary sources
is fluvoxamine fda approved for ocd in adults and children eight and older?
“It's approved for adults and for children eight and older.” — a host, at 01:32
this one holds up. the current FDA label for fluvoxamine immediate-release tablets lists OCD as the indication and gives dosing for adults and for children and adolescents aged 8 to 17.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-033 primary sources
does the fluvoxamine label allow adult ocd doses up to 300 mg a day?
“Its label already allows adult OCD doses up to 300 milligrams a day.” — a host, at 01:41
the speaker is right: every current fluvoxamine label we read caps the adult ocd dose at 300 mg a day, in those exact words: "not to exceed 300 mg per day." that applies to both the immediate-release tablets and the extended-release capsules.
- confirmedPsychopharmacology and Psychiatry Updates2026-10-034 primary sources
is fluvoxamine fda approved for major depression? no, its u.s. labels list only ocd
“Unlike several other SSRIs, it isn't FDA approved for major depression.” — a host, at 01:36
the host is right. every current FDA label we read for fluvoxamine, both the immediate-release tablets and the extended-release capsules, lists obsessive compulsive disorder as the only indication. major depressive disorder isn't there.
- confirmedThe Carlat Psychiatry Podcast2026-10-123 primary sources
do ssris lower pediatric ocd scores by only about 3 points more than placebo?
“On average, SSRIs reduce sidebox scores by about three points more than placebo, not very much.” — a host, a psychiatrist, at 03:07
the number is right. a 2025 individual-participant-data meta-analysis of four placebo-controlled trials in children and adolescents with OCD found that SSRIs lowered CY-BOCS scores by 3.0 points more than placebo (95% CI 2.5 to 3.5).
- confirmedPsychEd: Educational Psychiatry Podcast2026-09-013 primary sources
does the aripiprazole label call for half the dose with a strong cyp2d6 inhibitor like bupropion?
“air-pipersol's drug label recommends reducing its dose by half when coprescribed with a strong 2D6 inhibitor like bupropion.” — a host, a psychiatry resident, at 16:37
the speaker has the label right. the current aripiprazole prescribing information tells prescribers to "administer half of usual dose" when aripiprazole is taken with a strong CYP2D6 inhibitor, and FDA's own reference table lists bupropion as a strong CYP2D6 inhibitor.
- confirmedPsychEd: Educational Psychiatry Podcast2026-09-012 primary sources
can carbamazepine lower quetiapine levels by 80-90%? the primary record says yes
“carbamazepine can substantially lower quityapine levels, even by as much as 80-90%.” — a host, a psychiatry resident, at 08:55
the speaker has this right. in the dedicated interaction study, carbamazepine cut quetiapine peak levels by 80% and raised its clearance 7.5-fold, and a large drug-monitoring dataset found dose-corrected quetiapine levels 86% lower in people also taking carbamazepine.
- misattributedLex Fridman Podcast2026-09-205 primary sources
did 67% to 82% of catie patients quit their antipsychotic because it failed or because of side effects?
“Between 67% and 82% of the patients, depending on which drug they were on, dropped out of the trial because either the drug wasn't working or they couldn't stand the side effects.” — a guest, a historian of psychiatry (Andrew Scull), at 19:40
The trial is real and the scale is close: in the NIMH-funded CATIE trial, published in the New England Journal of Medicine in 2005, 74% of patients stopped their first assigned antipsychotic within 18 months. By drug, the rates ran from 64% to 82%, so the top of the speaker's range is exactly right.
- overstatedLex Fridman Podcast2026-09-204 primary sources
did the catie trial find the newer antipsychotics no more effective than the older drug?
“Are the new drugs more efficacious than the old drug? No.” — a guest, a historian of psychiatry (Andrew Scull), at 19:24
the core of this is right. in the CATIE trial, published in the New England Journal of Medicine in 2005, the older drug perphenazine did about as well as three of the four newer drugs tested (quetiapine, risperidone and ziprasidone), and the trial's funder, NIMH, summarized it as the newer drugs having "no substantial advantage" over the older one.
- overstatedLex Fridman Podcast2026-09-204 primary sources
does nice say cbt works better than antidepressants for milder depression?
“Uh and indeed, NICE, which is the British organization that passes on what treatments the National Health Service will support and which ones are uh sufficiently evidence-based, um has come to that same conclusion.” — a guest, historian of psychiatry (Andrew Scull), at 18:12
the policy part is right: england's 2022 depression guideline (ng222) says not to routinely offer antidepressants as first-line treatment for less severe depression unless the person prefers them, and it lists cbt among the options it puts ahead of medication.
- confirmedPsychEd: Educational Psychiatry Podcast2026-09-013 primary sources
does smoking lower clozapine and olanzapine levels by 30-50%?
“This induction can lower clasapine and olanzapine levels by as much as 30-50% compared to non-smokers.” — a host, a psychiatry resident, at 06:51
the speaker is right: tobacco smoke induces cyp1a2, and the main pooled analysis puts the gap at about 30% for olanzapine and about 50% for clozapine. the 30-50% range matches that meta-analysis.
- unverifiableThe Carlat Psychiatry Podcast2026-09-282 primary sources
did 15% of 687 psychiatry referrals get a brief phone consult instead of an assessment?
“Among the 687 referrals over seven months, only a small minority, 15%, were handled with this brief phone consultation.” — a host, a psychiatrist, at 13:46
the study exists and the frame is right: a 2026 Community Mental Health Journal quality-improvement paper reports that 687 outpatient psychiatry referrals were reviewed between November 2022 and May 2023, which is seven months, and that psychiatrist-led phone consultation was part of the new triage model. the first author's surname is spelled Guaiana in the record.
- confirmedPsychEd: Educational Psychiatry Podcast2026-10-013 primary sources
is bupropion contraindicated in people with current or past anorexia or bulimia?
“Bupropion is contraindicated in patients with current or prior and erectionerbosa, or bulimian herbosa.” — a host, a psychiatry resident, at 12:29
the resident has it right. us bupropion labels for both the immediate-release and extended-release tablets list a current or prior diagnosis of bulimia or anorexia nervosa as a contraindication, and the reason given is a higher rate of seizures.
- confirmedPsychEd: Educational Psychiatry Podcast2026-09-015 primary sources
are cyp2d6 poor metabolizers 5-10% of people of european ancestry?
“poor metabolizers make up roughly 5-10% of people of European ancestry,” — a host, a psychiatry resident, at 05:28
the band is right. the primary record puts cyp2d6 poor metabolizers in european-ancestry populations squarely inside 5-10%, and fda labels print that exact range.
- undersoldPsychEd: Educational Psychiatry Podcast2026-10-014 primary sources
is a heart rate below 40 the guideline line for urgent admission in eating disorders?
“Widely-sided indications for urgent admission can include a low heart rate below 40, with below 50 also being considered clinically significant.” — a host, a psychiatry resident, at 09:01
a resting heart rate below 40 does show up as an admission threshold in some eating-disorder guidance, and a heart rate below 50 is a recognized red flag. the speaker has both numbers in the right range.
- unverifiablePsychopharmacology and Psychiatry Updates2026-09-293 primary sources
did a new meta-analysis find trazodone cut depression scores by an smd of 0.365 across eight trials?
“Trasadone significantly reduces severity of depression compared to controls with the standardized mean difference of 0.365.” — a guest, Dr. Paul Sarkowski (clinician presenting the meta-analysis), at 04:37
the effect size is right. the 2026 meta-analysis in Psychopharmacology reports that trazodone reduced depression severity on the Hamilton Depression Rating Scale with an SMD of -0.365 (95% CI -0.480 to -0.249, p < 0.001), which matches the 0.365 the speaker quoted, and the result is statistically significant.
- unverifiablePsychopharmacology and Psychiatry Updates2026-09-293 primary sources
did a meta-analysis find trazodone improved sleep quality versus placebo by an smd of 0.827?
“The Trasadone group demonstrated significant improvements in sleep quality compared to placebo with a standardized mean difference of 0.827.” — a guest, Dr. Paul Sarkowski (clinician presenting the meta-analysis), at 04:15
the number is right. a 2025 meta-analysis in psychopharmacology reports that trazodone improved pittsburgh sleep quality index scores with a standardized mean difference of -0.827 (95% ci -1.331 to -0.323, p = 0.001), the same magnitude the speaker quoted, and the minus sign just means lower, better psqi scores.
- overstatedHuberman Lab2026-10-015 primary sources
do adhd stimulants and modafinil all increase dopamine in the brain
“there is of course aderall, rolin, vivance, modafanyl, arm modafanyl, a number of different compounds, all of which generally increase dopamine transmission in the brain.” — a host, a neuroscientist, at 33:05
The core of the statement holds up. FDA labels say amphetamines (including the dextroamphetamine that lisdexamfetamine turns into) and methylphenidate block dopamine reuptake and increase dopamine release. The modafinil and armodafinil labels say both drugs bind the dopamine transporter and block dopamine reuptake, and a human PET study measured higher extracellular dopamine after therapeutic doses of modafinil.
- overstatedPsychopharmacology and Psychiatry Updates2026-09-234 primary sources
does adding aripiprazole to another antipsychotic reliably lower prolactin?
“aeripipyzole specifically if you add it to an antipsychotic, it will actually reliably lower prolactin levels.” — a guest, a professor of psychiatry at Harvard Medical School, at 05:45
the core of the claim holds up. in randomized trials, adding aripiprazole to a prolactin-raising antipsychotic lowers prolactin more than placebo does, and a 2022 network meta-analysis rated the evidence for adjunctive aripiprazole as high certainty.
- misattributedLex Fridman Podcast2026-09-214 primary sources
do antidepressants beat placebo by only one or two points on depression scales?
“if you improve on one of the major scales that's used by one or two points on a 60-point scale, it may be enough to show statistical significance” — a guest, a historian of psychiatry (Andrew Scull), at 09:24
the speaker has the size right. on the scale most antidepressant trials used, the average gap between drug and placebo is about 1.8 to 2.1 points. that number is statistically solid, and it falls below the clinical-benefit cutoffs those same papers cite.
- confirmedHuberman Lab2026-09-285 primary sources
is compass pathways' psilocybin therapy close to fda approval?
“psilocybin coming from Compass uh a company called Compass Pathways is also close.” — a guest, author and journalist, at 1:48:38
the speaker is right: compass pathways' psilocybin program for treatment-resistant depression is the closest any classic psychedelic has come to a u.s. approval decision. two phase 3 trials met their primary endpoints, the fda allowed a rolling new drug application and gave the program a national priority voucher, and the company expects to finish its submission in q4 2026.
- confirmedThe Peter Attia Drive2026-10-054 primary sources
do guidelines recommend depression screening during pregnancy and after birth?
“Um we do have standard screening that's recommended during you know both during pregnancy for depression and um postpartum.” — a guest, an obstetrician (maternal-fetal medicine physician-scientist), at 34:23
the speaker is right. US guidelines recommend screening for depression both during pregnancy and after birth: the US Preventive Services Task Force does, obstetricians' and pediatricians' professional bodies have written guidance on it, and the task force's statement names pregnant and postpartum persons explicitly.
- confirmedLex Fridman Podcast2026-09-213 primary sources
do 40% or more of people with depression not respond to antidepressants?
“We're talking 40 or north of 40% who aren't responding.” — a guest, a historian of psychiatry (Andrew Scull), at 11:48
the number holds up. in the largest real-world antidepressant study the US government funded, about half of patients did not respond to the first drug they were given, so "40 or north of 40%" is a fair, even conservative, way to put it.
- overstatedHuberman Lab2026-09-283 primary sources
does one executive order fast-track both ibogaine and other psychedelics?
“The same um executive order that um is fasttracking Ibeane is fasttracking other psychedelics.” — a guest, author and journalist, at 1:48:17
the speaker is right. a single executive order, EO 14401 of april 18, 2026, names ibogaine and also directs federal agencies to speed up psychedelic drugs more broadly, so "the same order" covers both.
- confirmedPsychopharmacology and Psychiatry Updates2026-09-293 primary sources
did the fda approve trazodone for depression in 1981?
“The FDA approved Trasadone for depression back in 1981.” — a host, at 01:19
the host has this right. FDA's own approval database shows trazodone's original application was approved on december 24, 1981, as a new molecular entity, and the FDA label lists depression as the condition it treats.
- falseHuberman Lab2026-09-284 primary sources
is ibogaine on track for fda approval before mdma or psilocybin?
“Ibagane, the one psychedelic that no one's would even want to use recreationally, is going to get there first.” — a host, at 1:47:42
ibogaine does have real federal momentum. an april 2026 executive order names "ibogaine compounds" twice, and on october 5, 2026 the fda put out a formal request for input on how ibogaine trials should be run, alongside early-phase trials funded by arpa-h and nida.
- overstatedHuberman Lab2026-09-283 primary sources
has ibogaine never been tested in university drug trials?
“hasn't been, by the way, subjected to university drug trials,” — a guest, author and journalist, at 1:47:50
the most prominent university work on ibogaine, the stanford veterans study, is not a drug trial: stanford measured veterans before and after treatment, but the ibogaine itself was given at a private clinic near tijuana, and the paper says "stanford played no role in ibogaine administration." no randomized, placebo-controlled trial run by a university has shown that ibogaine itself works, and a 2026 review of thirty years of research says the evidence is not yet enough to support clinical use.
- confirmedThe Peter Attia Drive2026-10-053 primary sources
was medicaid postpartum coverage limited to 60 days before states extended it?
“Um it's been like 60 60 days.” — a guest, an obstetrician (maternal-fetal medicine physician-scientist), at 55:03
the speaker is right. federal medicaid law has long required pregnancy-related coverage through a 60-day postpartum period, and before 2022 most states stopped coverage at that point.
- overstatedHuberman Lab2026-10-016 primary sources
are methylphenidate, modafinil and armodafinil all stimulants used for adhd?
“rolin, modafanyl, arm modafanyl, all these things are stimulants.” — a host, a neuroscientist, at 34:24
The speaker is right that all three count as stimulants in the federal record: methylphenidate's label calls it a central nervous system stimulant, and the drug enforcement agency's rule scheduling modafinil calls it "a central nervous system (CNS) stimulant", covering its isomers, which includes armodafinil. The claim goes further than the record on ADHD: only methylphenidate is approved for it.
- overstatedLex Fridman Podcast2026-09-213 primary sources
does nice tell clinicians in england to use cbt rather than antidepressants first?
“groups like NICE in England are saying use CBT as the first line, not drugs.” — a guest, a historian of psychiatry (Andrew Scull), at 11:07
this part is true: england's depression guideline (nice ng222, june 2022) tells clinicians not to routinely offer antidepressants as first-line treatment for less severe depression unless the person makes an informed choice to take them, and cbt is one of the first-line options it recommends. in the evidence review nice commissioned, antidepressants showed no evidence of effect in less severe depression, and group cbt did.
- confirmedHuberman Lab2026-10-015 primary sources
is taking someone else's adhd stimulant illegal and risky for addiction and side effects?
“they can have a number of other side effects outside the context of clinically diagnosed and prescribed ADHD medication.” — a host, a neuroscientist, at 35:17
The claim holds up. In the u.s., having a prescription stimulant you weren't prescribed is a federal crime, and the fda's own 2023 safety notice says nonmedical use is linked to a higher risk of substance use disorder and can lead to overdose and death.
- confirmedHuberman Lab2026-10-014 primary sources
do stimulants calm children with adhd instead of making them more hyperactive?
“giving that to a kid who has severe ADHD, you would think would make them rem more rambunctious, less able to focus, and more distractable overall.” — a host, a neuroscientist, at 34:12
the speaker is right on the main point: in randomized trials, stimulants given to children with adhd lower hyperactivity and inattention ratings over the short term. they do not make those symptoms worse.
- unverifiablePsychopharmacology and Psychiatry Updates2026-09-293 primary sources
did blurred vision have an odds ratio of 18 in the trazodone-for-sleep-in-depression meta-analysis?
“As per side effects, blurred vision was most common with an odds ratio of 18 compared to placebo.” — a guest, Dr. Paul Sarkowski (clinician presenting the meta-analysis), at 05:02
The number is real. A 2026 meta-analysis of trazodone for sleep problems in depression reports an odds ratio for blurred vision of 17.50, which rounds to the 18 the speaker gave.
- misattributeda Substack newsletter2026-03-104 primary sources
are toddlers on medicaid being put on anti-anxiety drugs in large numbers
“we call it medicine: the mass psychiatric drugging of poor children” — a author, a clinical psychologist writing on his own newsletter, at 00:00
The underlying worry is real and the public record backs it: in the 2025 reporting year the median state documented first-line psychosocial care for only 59.2 percent of children aged 1 to 11 starting an antipsychotic, got both required metabolic blood tests for 29.1 percent of young children on two or more antipsychotic prescriptions, and saw 47.6 percent of children newly prescribed an ADHD medicine again within 30 days. Those are the states' own numbers.
what this is not
not medical advice, and not a reason to start, stop or change a medication; those decisions belong with the person taking it and their prescriber. not a takedown of any host or guest: small true errors stay off the public reply and live only here, because including them turns a contribution into a takedown. and not a feed we re-host: every entry links the original at the timestamp and quotes one sentence under fair use.
if you have the file behind a claim we marked unverifiable, we want it. the research board is the place; people can answer there.